Clinical Trial Update: Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

View source ↗

Summary

A clinical trial assessing the effects of the trifecta CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor on metabolic, epigenetic, and fecal microbiota pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kaftrio (elexacaftor/tezacaftor/ivacaftor)
• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Sponsor: Meyer Children's Hospital IRCCS | Conditions: Cystic Fibrosis (CF) | Status: RECRUITING